Search Browse Earnings

Akero Therapeutics, Inc.

Pharmaceutical Preparations·SOUTH SAN FRANCISCO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Akero Therapeutics, Inc. — SlamSEC

Revenue

—

Adj. EBITDA

-$115.1M

FY 2024

Net Income

-$112.0M

FY 2024

EPS (Diluted)

-$2.87

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$234.2M

FY 2024

Total Debt

—

Net Cash

$234.2M

Enterprise Value

—

Debt / EBITDA

2.0x

FY 2024

EV / EBITDA

—

Employees

—